TYTakuki Yagyu

Takuki Yagyu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takuki Yagyu has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Yoshiyuki Fujiwara

    Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, School of Medicine, Tottori University, Tottori, Yonago, Japan

    13 shared publications
  • Teruhisa Sakamoto

    Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, School of Medicine, Tottori University, Tottori, Yonago, Japan

    12 shared publications
  • Naruo Tokuyasu

    Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago, Japan

    9 shared publications
  • Ei Uchinaka

    Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago, Japan

    7 shared publications
  • Joji Watanabe

    Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago, Japan

    7 shared publications
  • Manabu Yamamoto

    Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, School of Medicine, Tottori University, Tottori, Yonago, Japan

    7 shared publications

Latest Publications

  • Clinical impact of adjuvant chemotherapy and regimen selection in Stage III colorectal cancer with impaired performance status: a multicenter cohort study

    by Takuki Yagyu, Manabu Yamamoto, Chihiro Uejima, Akimitsu Tanio, Yasuro Kurisu, Shunsuke Shibata, Akemi Iwamoto, Takuji Naka, Yusuke Kono, Kyoichi Kihara, et al.

    Background The optimal use of adjuvant chemotherapy (ACT) in patients with impaired performance status (PS) has not been reliably determined, particularly regarding intensification of treatment with oxaliplatin (OX). In this study, we evaluated the clinical impact of ACT and OX in patients with Stage III colorectal cancer (CRC) and impaired PS. Methods The cohort of this multicenter retrospective study comprised 566 patients with Stage III CRC and PS ≥ 1 who had undergone curative resection. Propensity score matching was used to compare outcomes between ACT (+) and ACT (−) groups. Additionally, stabilized inverse probability of treatment weighting was performed to compare outcomes of fluoropyrimidine (FP) monotherapy and OX-based regimens. The primary endpoint was disease-free survival (DFS). Results After propensity score matching, ACT (+) was associated with significantly longer DFS than ACT (−) (HR 0.573, P = 0.003), with consistent findings for relapse-free survival, overall survival, and sensitivity analyses. Inverse probability of treatment weighting analyses showed that OX-based regimens did not achieve significantly longer DFS than did FP monotherapy (HR 1.143, P = 0.705). Exploratory subgroup analyses showed shorter DFS with OX in high-risk disease, but not in low-risk disease. Conclusions ACT was associated with improved survival, even in patients with impaired PS. In contrast, OX-based combination therapy did not demonstrate a statistically significant additional survival benefit over fluoropyrimidine monotherapy in this cohort. These findings suggest that treatment strategies for Stage III CRC with impaired PS should be individualized, with careful consideration of the patient’s condition rather than routinely intensifying treatment.

  • Open Access

    Clinical impact of adjuvant chemotherapy and regimen selection in Stage III colorectal cancer with impaired performance status: A multicenter cohort study

    by Takuki Yagyu, Manabu Yamamoto, Chihiro Uejima, Akimitsu Tanio, Yasuro Kurisu, Shunsuke Shibata, Akemi Iwamoto, Takuji Naka, Yusuke Kono, Kyoichi Kihara, et al.

    Background The optimal use of adjuvant chemotherapy (ACT) in patients with impaired performance status (PS) has not been reliably determined, particularly regarding intensification of treatment with oxaliplatin (OX). In this study, we evaluated the clinical impact of ACT and OX in patients with Stage III colorectal cancer (CRC) and impaired PS. Methods The cohort of this multicenter retrospective study comprised 566 patients with Stage III CRC and PS ≥ 1 who had undergone curative resection. Propensity score matching was used to compare outcomes between ACT (+) and ACT (−) groups. Additionally, stabilized inverse probability of treatment weighting was performed to compare outcomes of fluoropyrimidine (FP) monotherapy and OX-based regimens. The primary endpoint was disease-free survival (DFS). Results After propensity score matching, ACT (+) was found to be associated with significantly longer DFS than ACT (−) (HR 0.45, P < 0.001), with consistent benefits observed for relapse-free survival and overall survival. Inverse probability of treatment weighting analyses showed that OX-based regimens did not achieve significantly longer DFS than did FP monotherapy (HR 0.85, P = 0.603). Subgroup analyses showed that OX conferred no clear benefit, including in patients with high-risk Stage III. Conclusions ACT was associated with improved survival, even in patients with impaired PS. In contrast, OX-based regimen intensification did not provide a clear additional survival benefit. These findings suggest that treatment strategies for Stage III CRC with impaired PS should be individualized, with careful consideration of the patient’s condition rather than routinely intensifying treatment.

  • Open Access

    Clinical impact of diverting ileostomy and high-output stoma on adjuvant chemotherapy for rectal cancer: a retrospective cohort study

    by Takuki Yagyu, Manabu Yamamoto, Kei Urakami, Kotaro Osaki, Chiharu Yasui, Yusuke Kono, Kyoichi Kihara, Tomoyuki Matsunaga, Naruo Tokuyasu, Teruhisa Sakamoto, et al.

    Purpose Diverting ileostomy (DI) may cause fluid and electrolyte loss, potentially impairing the tolerability of adjuvant chemotherapy (ACT) in patients with rectal cancer. However, its clinical impact, especially in the presence of high-output stoma (HOS), remains unclear. This study aimed to evaluate the effects of DI and perioperative HOS on chemotherapy completion, dose intensity, and the incidence of severe adverse events (AEs). Methods We retrospectively analyzed 107 patients with rectal cancer who underwent curative resection and received postoperative ACT between June 2012 and December 2024 at Tottori University. Chemotherapy completion, relative dose intensity (RDI), and grade ≥ 3 AEs were compared between patients with and without DI. A subgroup analysis assessed the influence of HOS among DI patients. Results Chemotherapy completion rate and RDI were comparable between patients with and without DI. However, the incidence of grade ≥ 3 AEs was significantly higher in the DI group than in the non-DI group (18.2% vs. 4.1%, P = 0.015), and DI was identified as an independent risk factor in multivariate analysis (odds ratio [OR] 5.749, P = 0.022). Among patients with DI, those with HOS had a significantly lower oxaliplatin RDI than those without HOS (37.5% vs. 75.0%, P = 0.007), and HOS independently predicted failure to complete oxaliplatin-based regimens (OR 13.423, P = 0.039). Conclusions While DI does not impair overall chemotherapy delivery, it is associated with increased early toxicity. HOS may compromise oxaliplatin administration and should prompt early recognition and targeted supportive interventions.


  • Open Access

    Laparoscopic resection of a cecal carcinoma with a Retzius vein shunt: A case report

    by Yusuke Kono, Manabu Yamamoto, Chiharu Yasui, Ryo Ishiguro, Takuki Yagyu, Kyoichi Kihara, Tomoyuki Matsunaga, Shuichi Takano, Naruo Tokuyasu, Teruhisa Sakamoto, et al.

    Rationale: A Retzius shunt between the ileocecal vein and inferior vena cava is rare. To avoid major hemorrhage due to shunt injury, it is essential to evaluate vascular abnormalities on preoperative imaging and to confirm anatomic structures in detail during the operation. Patient concerns: A 71-year-old woman with diabetes and asthma developed anaemia. Diagnoses: She was diagnosed with cecal cancer by endoscopy and found to have a venous malformation forming a Retzius shunt from the ileocecal vein to the inferior vena cava on computed tomography. Intervention: Laparoscopic ileocecal resection was performed. Colonic mobilization and resection of the ileocecal vessels were performed while minimizing traction on the shunt. After confirming the anatomy, the Retzius shunt was resected without complications. Outcomes: The patient experienced an unremarkable postoperative clinical course without complications. Lessons: This case involved a rare vascular anomaly associated with colorectal cancer, characterized by an abnormal blood vessel connecting the inferior vena cava and mesenteric veins. When abnormal vessels are detected on preoperative abdominal computed tomography, a Retzius shunt should be considered. Detailed review of the imaging, careful surgical manipulation to avoid shunt damage, and thorough anatomical verification, are important to perform a safe operation.


  • Open Access

    Rectal Resection with Hysterectomy for Locally Advanced Rectal Cancer Using the hinotori Surgical Robot System: The First Ever Case Report

    by Takuki Yagyu, Manabu Yamamoto, Hiroaki Komatsu, Chiharu Yasui, Ryo Ishiguro, Yusuke Kono, Kyoichi Kihara, Yuki Iida, Tomoyuki Matsunaga, Naruo Tokuyasu, et al.

    The number of reports of robotic surgery for rectal cancer with combined resection of other organs is increasing gradually, with most procedures performed using the da Vinci Surgical System. The hinotori Surgical Robot System, developed in Japan, was approved for gastrointestinal surgery and gynecology in 2022. Here, we report the first case of en-bloc rectal resection with hysterectomy using the hinotori Surgical Robot System. A 77-year-old woman was referred to our institution with a diagnosis of rectal cancer (cT4bN1bM1a), with uterine invasion and a resectable liver metastasis. We performed rectal resection with total hysterectomy and bilateral salpingo-oophorectomy using the hinotori Surgical Robot System. Two surgical teams, a gastroenterological team and a gynecological team, performed en-bloc resection of the rectum and uterus. Because of in-depth consultation between the teams, the operation was performed safely with no unplanned additional ports, robotic arm interference or arm collision with the assistant surgeon. Including the preceding stoma closure, the operative time was 473 minutes, and blood loss was 60 mL. The patient experienced no complications ≥ Clavien–Dindo classification grade III. Robot-assisted extended surgery for locally advanced rectal cancer using the hinotori Surgical Robot System can be performed safely, which may lead to an expanded treatment option in the future.


  • Laparoscopic Repair of Internal Hernia at the Pelvic Floor After Low Anterior Resection: A Case Report

    by Takuki Yagyu, Manabu Yamamoto, Chiharu Yasui, Ryo Ishiguro, Yusuke Kono, Kyoichi Kihara, Tomoyuki Matsunaga, Naruo Tokuyasu, Teruhisa Sakamoto, Yoshiyuki Fujiwara

    Internal hernia following colorectal surgery is an uncommon but serious complication. Most reported cases have involved hernias resulting from mesenteric defects after left‐sided colon resection. We herein report a case of laparoscopic repair of an internal hernia at the pelvic floor following low anterior resection. A 78‐year‐old woman with a history of robotic low anterior resection for rectal cancer presented to our hospital with severe abdominal pain and vomiting. Computed tomography revealed a strangulated bowel passing dorsally behind the reconstructed colon in the pelvis, prompting emergency surgery. The hernia orifice was formed by the levator ani and the reconstructed colon. We successfully reduced the hernia, laparoscopically sutured the orifice, and resected the strangulated bowel segment. The patient was discharged without complications and has experienced no hernia recurrence to date. Although internal hernia at the pelvic floor is very rare, this case demonstrates that safe laparoscopic reduction and repair are possible.


  • Open Access

    Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study

    by Takuki Yagyu, Manabu Yamamoto, Akimitsu Tanio, Kazushi Hara, Ken Sugezawa, Chihiro Uejima, Kyoichi Kihara, Shigeru Tatebe, Yasuro Kurisu, Shunsuke Shibata, et al.

    Adjuvant chemotherapy for stage II colorectal cancer (CRC) is considered appropriate for patients with risk factors for recurrence, rather than for all patients uniformly. However, the risk factors for recurrence remain controversial, and there is limited information, especially for elderly patients. The Geriatric Nutritional Risk Index (GNRI) is widely used as a simple nutritional screening tool in the elderly and is associated with cancer prognosis and recurrence. This study aimed to investigate the risk factors for recurrence in the elderly with stage II CRC, focusing on the GNRI. We enrolled 348 elderly patients (≥ 75 years) with stage II CRC who underwent curative resection at the Department of Surgery, Tottori University and our 10 affiliated institutions. The patients were divided into GNRIhigh (≥ 93.465) and GNRIlow (< 93.465) groups. The GNRIlow group showed a significantly worse overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) (P < 0.001, P < 0.001, and P < 0.001, respectively). In a multivariate analysis, GNRIlow (hazard ratio [HR]: 2.244, P < 0.001), pathologic T4 stage (HR: 1.658, P = 0.014), and moderate to severe lymphatic or venous invasion (HR: 1.460, P = 0.033) were independent factors affecting RFS. By using these three factors to score the risk of recurrence from 0 to 3 points, the prognosis was significantly stratified in terms of OS, CSS, and RFS (P < 0.001, P < 0.001, and P < 0.001, respectively). The recurrence rate for each score was as follows: 0 points, 9.8%; 1 point, 22.0%; 2 points, 37.3%; and 3 points, 61.9%. GNRIlow, pathologic T4 stage, and moderate to severe lymphatic or venous invasion are high-risk factors for recurrence in the elderly with stage II CRC. The scoring system using these three factors appropriately predicted their recurrence and outcome.


  • Open Access

    A Novel Noninvasive Method for Predicting Liver Fibrosis by Quantifying the Estrangement of Indocyanine Green Retention Rate and Tc-99m-diethylenetriamine-penta-acetic Acid-galactosyl Human Serum Albumin Scintigraphy

    by Takehiko Hanaki, Ei Uchinaka, Takuki Yagyu, Masaki Morimoto, Joji Watanabe, Kozo Miyatani, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Yoji Fukumoto, et al.

    Background/Aim: Indocyanine green (ICG) clearance test is one of the most popular dynamic methods for evaluating preoperative liver function to avoid posthepatectomy liver failure (PHLF). Tc-99m-diethylenetriamine-penta-acetic acid-galactosyl human serum albumin scintigraphy (GSA) also facilitates the direct estimation of functional hepatocytes and can estimate the ICG retention rate (R15); however, in some cases, there is a discrepancy between results of a preoperative examination of ICG-R15 and the estimated ICG-R15 obtained by 99mTc-GSA (GSA-R15). This study evaluated the gap between ICG-R15 and GSA-R15 (ΔICG) for predicting background liver fibrosis in patients who underwent hepatectomy. Patients and Methods: Sixty-four consecutive patients who underwent hepatectomy and preoperative ICG-R15 and GSA-R15 examinations from 2016 to 2019 were retrospectively evaluated. The gap between GSA-R15 and ICG-R15 was defined as ΔICG and the factors predicting liver fibrosis were investigated. Results: In the pathologically-proven cirrhotic group, platelet counts were significantly lower and ΔICG values were significantly larger than those in the non-/early-cirrhotic group. A multivariate analysis identified a higher total bilirubin level, a higher AST level, and a larger ΔICG level as significant predictive factors for liver cirrhosis. Conclusion: Larger ΔICG was found to be an independent preoperative predictor of liver fibrosis and may positively contribute to decision-making before hepatectomy to avoid PHLF.


  • Open Access

    Laparoscopically-Assisted Repair of a Small Bowel Perforation Secondary to Multiple Metastases of Undifferentiated Pleomorphic Sarcoma

    by Masaki Morimoto, Soichiro Honjo, Teruhisa Sakamoto, Takuki Yagyu, Ei Uchinaka, Takehiko Hanaki, Joji Watanabe, Tomoyuki Matsunaga, Manabu Yamamoto, Yoji Fukumoto, et al.

    We present a very rare case of a laparoscopically-assisted repair of a small bowel perforation secondary to multiple metastases of undifferentiated pleomorphic sarcoma from the posterior mediastinum. A 46-year-old man presented with middle to upper abdominal pain during chemotherapy for lung metastases from undifferentiated pleomorphic sarcoma. Computed tomography revealed intra-abdominal free air, and emergency laparoscopy was performed. Consequently, a perforation was detected in the jejunum, and partial jejunal resection was performed by mini-laparotomy. Pathological examination demonstrated an ulcerated tumor with perforation and four additional tumors in the resected jejunum. Pathological examination also revealed undifferentiated pleomorphic sarcoma in all five tumors. To our knowledge, our case is the first report of a laparoscopically-assisted repair of a small bowel perforation secondary to metastasis of undifferentiated pleomorphic sarcoma. Although the perforation site was unclear preoperatively, laparoscopic observation readily identified the lesion in this patient. Therefore, minimally invasive surgery could be performed successfully with mini-laparotomy following laparoscopic observation. Laparoscopic techniques for the small intestine are viable options, even in acute and uncommon situations, and small bowel perforation secondary to metastasis should be considered in patients with undifferentiated pleomorphic sarcoma and acute abdomen.


  • Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients

    by Masaki Morimoto, Soichiro Honjo, Teruhisa Sakamoto, Takuki Yagyu, Ei Uchinaka, Takehiko Hanaki, Joji Watanabe, Tomoyuki Matsunaga, Manabu Yamamoto, Yoji Fukumoto, et al.

    Background C-reactive protein (CRP) levels reflect ongoing inflammation and/or tissue damage, and studies suggest that platelets play a role in tumor invasion and metastasis. P-CRP is defined as the multiplied product of serum CRP and platelet levels. Here the prognostic value of pre- and post-operative P-CRP levels in pancreatic cancer (PC) patients was assessed.Methods This retrospective study used data from 107 consecutive PC patients who had undergone either pancreaticoduodenectomy or distal pancreatectomy. Clinicopathological parameters and pre/post-operative laboratory data derived from patient records were used for analyses. P-CRP was defined as the product of peripheral thrombocyte count (/uL) × serum CRP level (mg/dL) divided by 104; the optimal P-CRP cut-off value was defined using receiver operating characteristic curves.Results PC patients were classified as either P-CRPLow (< 1.782; n = 49) or P-CRPHigh (≥ 1.782; n = 58), based on the cut-off value of 1.782. Univariate analysis revealed that performance status, clinical stage, pathological T and N stages, P-CRP, and carbohydrate antigen 19-9 (CA19-9) significantly affected overall survival (OS). Multivariate analysis revealed that independent risk factors for OS were pathological N stage, P-CRP, and CA19-9. Additionally, 103 PC patients for whom postoperative data were available were classified into four groups (P-CRPLow-Down, P-CRPLow-Up, P-CRPHigh-Down and P-CRPHigh-Up), based on preoperative P-CRP and postoperative trend of P-CRP, and we found that prognosis, in terms of OS, was significantly different among these groups (P = 0.012).Conclusion Pre- and post-operative P-CRP values are a potential predictor of prognosis in PC patients.